Inversago Pharma Appoints Michael D. Harvey, PhD as Senior Vice President, Drug Development

Oct. 13, 2020 12:00 UTC

 

 
 

MONTREAL--(BUSINESS WIRE)-- Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Senior Vice President, Drug Development. In his position, Dr. Michael Harvey will be responsible for overseeing all R&D activities pertaining to CMC, nonclinical development, and regulatory affairs.

“As we grow our operations, I am pleased to welcome Michael to our leadership team”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma. “For nearly two decades, Michael has been steadily focused on drug development and regulatory affairs, with extensive experience in the rare disease space, a high value asset for Inversago as we roll out our clinical programs in the years ahead”, added Dr. Ravenelle.

“I am thrilled to be joining Inversago Pharma as it enters the clinical phase of development of INV-101, and look forward to advancing its portfolio of CB1 inverse agonists to serve patients with unmet medical needs”, said Michael Harvey, PhD, Senior Vice President of Drug Development of Inversago Pharma.

Dr. Michael Harvey has been working in the biotechnology industry throughout his career, most recently as Vice President, Drug Development and Montreal Site Head at Ipsen (formerly Clementia Pharmaceuticals Inc.). He previously assumed increasing managing roles at Thallion Pharmaceuticals and several other biotech companies. Dr. Harvey holds a BSc in Biology and a PhD in Bioanalytical Chemistry, both from Concordia University (Montreal, Canada).

About Inversago Pharma

Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com.

Picture of Dr. Harvey available for download at: inversago.com/en/media/

Contacts

François Ravenelle, PhD
CEO & Founder
Inversago Pharma inc.
info@inversago.com

 
 

Source: Inversago Pharma Inc.

Back to news